Author:
Harris Katherine E.,Lorentsen Kyle J.,Malik-Chaudhry Harbani K.,Loughlin Kaitlyn,Basappa Harish Medlari,Hartstein Sharon,Ahmil Ghenima,Allen Nicole S.,Avanzino Brian C.,Balasubramani Aarti,Boudreau Andrew A.,Chang Karen,Cuturi Maria-Cristina,Davison Laura M.,Ho Dennis M.,Iyer Suhasini,Rangaswamy Udaya S.,Sankaran Preethi,Schellenberger Ute,Buelow Roland,Trinklein Nathan D.
Abstract
AbstractThe use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events and limited efficacy of IL-2 treatment are due to the preferential binding of IL-2 to cells that express the high-affinity, trimeric receptor, IL-2Rαβγ such as endothelial cells and T-regulatory cells, respectively. Here, we describe a novel bispecific heavy-chain only antibody which binds to and activates signaling through the heterodimeric IL-2Rβγ receptor complex that is expressed on resting T-cells and NK cells. By avoiding binding to IL-2Rα, this molecule circumvents the preferential T-reg activation of native IL-2, while maintaining the robust stimulatory effects on T-cells and NK-cells in vitro. In vivo studies in both mice and cynomolgus monkeys confirm the molecule’s in vivo biological activity, extended pharmacodynamics due to the Fc portion of the molecule, and enhanced safety profile. Together, these results demonstrate that the bispecific antibody is a safe and effective IL-2R agonist that harnesses the benefits of the IL-2 signaling pathway as a potential anti-cancer therapy.
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. Rosenberg, S. A. IL-2: The first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458 (2014).
2. Lotze, M. T. et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. Baltim. Md. 1950(135), 2865–75 (1985).
3. Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142–1151 (2005).
4. Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180–190 (2012).
5. Waldmann, T. A. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595–601 (2006).
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献